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ABSTRACT
Background Antiplatelet agents are increasingly used 
in cardiovascular treatment. Limited research has been 
performed into risks of acute and delayed traumatic 
intracranial hemorrhage (ICH) in these patients who 
sustain head injuries. Our goal was to assess the overall 
odds and identify factors associated with ICH in patients 
on antiplatelet therapy.
Methods A retrospective observational study was 
conducted at two level I trauma centers. Adult patients 
with head injuries on antiplatelet agents were enrolled 
from the hospitals’ trauma registries. Acute ICH was 
diagnosed by head CT. Observation and repeat CT to 
evaluate for delayed ICH was performed at clinicians’ 
discretion. Patients were stratified by antiplatelet type 
and analyzed by ICH outcome.
Results Of 327 patients on antiplatelets who 
presented with blunt head trauma, 133 (40.7%) had 
acute ICH. Three (0.9%) had delayed ICH on repeat CT, 
were asymptomatic and did not require neurosurgical 
intervention. One with delayed ICH was on clopidogrel 
and two were on both clopidogrel and aspirin. Patients 
with delayed ICH compared with no ICH were older (94 
vs 74 years) with higher injury severity scores (15.7 vs 
4.4) and trended towards lower platelet counts (141 
vs 216). Patients on aspirin had a higher acute ICH 
rate compared with patients on P2Y12 inhibitors (48% 
vs 30%, 18% difference, 95% CI 4 to 33; OR 2.18, 
95% CI 1.15 to 4.13). No other group comparison had 
significant differences in ICH rate.
Conclusions Patients on antiplatelet agents with head 
trauma have a high rate of ICH. Routine head CT is 
recommended. Patients infrequently developed delayed 
ICH. Routine repeat CT imaging does not appear to be 
necessary for all patients.
Level of evidence Level III, prognostic.
INTRODUCTION
Antiplatelet agents are increasingly being used 
in the treatment or prevention of cardiovascular 
disease.1 2 Patients taking these medications appear 
to have an increased risk of traumatic bleeding.3–10 
When patients suffer head trauma, an intracranial 
hemorrhage (ICH) can occur acutely or delayed. A 
number of studies have looked at acute traumatic 
ICH in patients taking an antiplatelet agent, with 
ICH occurring in approximately 3.6%–67.3% of 
patients on antiplatelet therapy and 1.6%–50.5% 
of patients not on this therapy.5 The reported risk 
of delayed ICH after head injury has varied in the 
literature from 0% to 4%.10–16
Several clinical guidelines highlight the risk of 
traumatic delayed ICH in patients taking anti-
platelet agents.17–19 According to the 2014 National 
Institute of Health and Care Excellence guidelines 
on head injury, for patients on aspirin or clopido-
grel, ‘the reference standard should include CT 
head scan and a follow- up period of sufficient 
duration to capture delayed bleeding, for example, 
at 7 days and 1 month’.17 Nonetheless, neither 
The American College of Surgeons Resources for 
Optimal Care of the Injured Patient, sixth edition 
released in 2014 nor the Recommendations of the 
National Expert Panel on Field Triage published by 
the Center for Disease Control and Prevention in 
2011 include head trauma or fall in a patient taking 
an antiplatelet as a criterion for trauma activa-
tion.18 19 In addition, the current American College 
of Emergency Physicians’ clinical guidelines do not 
specifically list antiplatelet medications as a risk 
factor for traumatic ICH.20
With the limited amount of available research 
regarding the risk of both acute and delayed ICH, 
and the varying methodology and quality of the 
literature in patients taking antiplatelet agents, the 
objective of our study was to assess the odds of 
acute and delayed ICH among head trauma victims 
with pre- injury exposure to antiplatelet agents.
METHODS
Study design and setting
This multicenter retrospective investigation was 
conducted at two level I trauma centers between 
January 1, 2016 and December 31, 2017. The first 
site of investigation in central Michigan is a 68- bed 
emergency department (ED) with annual census 
of 100 000 patients and 676 inpatient beds. The 
second site in southeast Florida is a 36- bed ED with 
annual census of 70 000 patients and 463 inpatient 
beds.
Selection of participants
The trauma registry at each hospital was queried 
for inclusion criteria of patients with pre- injury use 
of antiplatelet therapy (defined as aspirin, clopido-
grel, prasugrel and ticagrelor) seen in the ED by 
the trauma team for any head trauma. Exclusion 
criteria were age <18 years, no use of antiplatelet 
therapy in the last 7 days, prior use of an anticoag-
ulant and those suffering head trauma >24 hours 
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prior to ED presentation. All patients meeting these criteria were 
included, making up the study sample. Trauma activation at both 
hospitals was determined by the prehospital paramedics, who 
followed local protocols that mirror the CDC Guidelines for 
Field Triage of Injured Patients.19 Antiplatelet use alone did not 
warrant trauma activation in the study population. Within the 
ED, patients also may have been upgraded to the trauma service 
at treating physicians’ discretion.
Measurements
At both hospitals, the typical trauma workup in the ED consisted 
of complete blood count, comprehensive metabolic panel, coag-
ulation studies (prothrombin time, international normalized 
ratio (INR) and partial thromboplastin time) and head CT. Some 
patients on antiplatelet therapy were admitted for neurological 
observation and repeat head CT based on clinician discretion, 
although neither hospital had practice management guidelines 
dictating such.
A standardized data abstraction form was used that included 
the following: age, sex, ethnicity, mechanism of injury, signs and 
symptoms, Glasgow Coma Scale (GCS), injury severity score, 
initial vital signs, platelet count, coagulation studies, findings 
of initial head CT, findings of repeat head CT, performance of 
neurosurgical intervention and mortality. Radiographic imaging 
was interpreted by board- certified radiologists at both institu-
tions. All data were obtained by chart review from the respective 
hospitals’ electronic medical records by one of the coauthors at 
each institution.
Outcomes
The primary outcome of the study was the presence of acute or 
delayed ICH. An acute ICH is defined as having an acute intra-
cranial bleed on the initial head CT. A delayed ICH is defined as 
having an acute finding of intracranial bleeding on the repeat CT 
after an initial negative CT. Secondary outcomes included need 
for neurosurgical intervention and mortality during the hospi-
talization. Neurosurgical intervention was defined as the perfor-
mance, use or placement of an intracranial pressure monitor, an 
intraventricular catheter, a subdural drain, a craniotomy/craniec-
tomy or treatment with mannitol or hypertonic saline.
Analysis
Patients were grouped by aspirin alone, P2Y12 alone or aspirin 
with P2Y12. Background characteristics of patients were 
compared between antiplatelet categories at a significance level 
of 0.05 using z- tests for proportions and t- tests for means. 
Patients in each antiplatelet group were analyzed by primary 
outcome (no ICH, acute ICH and delayed ICH). Pearson’s χ2 
tests were performed and odds ratios were calculated using Stata 
V.16 (StataCorp, College Station, Texas, USA) to compare the
rates of acute and delayed ICH between each of the antiplatelet
groups. The types of ICH (epidural, subdural, subarachnoid and
intraparenchymal) were identified for each antiplatelet category.
The reason for repeat head CT (routine, clinical change or not
repeated) was identified for each primary outcome group. Any
patients with missing data points were excluded from only that
portion of the analysis.
RESULTS
Characteristics of study subjects
Three hundred twenty- seven patients were included in the anal-
ysis: 128 patients on aspirin only, 60 on clopidogrel only, 3 on 
ticagrelor only, 0 on prasugrel only, 128 on both aspirin and 
clopidogrel, 6 on both aspirin and ticagrelor and 2 on both 
aspirin and prasugrel. Overall, the average patient age was 
76 years (range 18–97), 43% were female and patients were 
predominantly Caucasian (87%). The majority of head injuries 
occurred as the result of falls (81%), followed by motor vehicle 
collisions (10%). Grouping the patients by antiplatelet classifi-
cation, 63 patients were on a P2Y12 inhibitor alone and 136 
patients were on both aspirin and a P2Y12 inhibitor. Background 
characteristics of patients between groups were mostly similar, 
although notably, the aspirin+P2Y12 inhibitor group had more 
motor vehicle crashes than the P2Y12 group and patients in the 
aspirin group had higher rates of signs of head trauma and loss 
of consciousness than the aspirin+P2Y12 group (table 1).







Age, mean (SD), years 75 (13) 76 (13) 76 (13)
Female, no. (%) 57 (45%) 27 (43%) 57 (42%)
Ethnicity, no. (%)
 Caucasian 111 (87%) 54 (86%) 119 (88%)
 African- American 10 (8%) 6 (10%) 7 (5%)
 Hispanic/Latino 6 (5%) 3 (5%) 7 (5%)
  Other 1 (1%) 0 (0%) 3 (2%)
Mechanism of injury, no. (%)
 Fall 100 (78%) 56 (89%) 110 (81%)
 Motor vehicle crash 14 (11%) 1 (2%)* 19 (14%)*
 Bicycle accident 2 (2%) 2 (3%) 1 (1%)
 Motorcycle accident 3 (2%) 0 (0%) 1 (1%)
 Pedestrian struck by vehicle 5 (4%) 1 (2%) 2 (1%)
 Blunt injury to head (not fall) 3 (2%) 3 (5%) 2 (1%)
  Other 1 (1%) 0 (0%) 1 (1%)
Signs of head trauma, no. (%) 113 (88%)* 52 (83%) 99 (73%)*
Symptoms, no. (%)
 Loss of consciousness 55 (43%)* 22 (35%) 31 (23%)*
 Headache 63 (49%) 32 (51%) 52 (38%)
 Seizure 1 (1%) 1 (2%) 2 (1%)
 Nausea 5 (4%) 5 (8%) 10 (7%)
 Vomiting 3 (2%) 3 (5%) 5 (4%)
  Dizziness 5 (4%) 5 (8%) 11 (8%)
Initial GCS group, no. (%)
 Mild (13–15) 119 (93%) 61 (97%) 129 (95%)
 Moderate (9–12) 5 (4%) 2 (3%) 4 (3%)
  Severe (3–8) 4 (3%) 0 (0%) 3 (2%)
Injury severity score, mean (SD) 10 (9) 9 (10) 12 (13)
Initial vital signs, mean (SD)
 Systolic blood pressure, mmHg 147 (30) 148 (24) 145 (27)
 Diastolic blood pressure, mmHg 76 (18) 76 (18) 74 (18)
 Heart rate, beats/min 85 (17)* 81 (15) 79 (18)*
 Respiratory rate, breaths/min 19 (4)* 18 (3) 18 (2)*
 Oxygen saturation, % 97 (3) 96 (5) 96 (8)
Platelet count, mean (SD), ×109/L 218 (63) 209 (64) 208 (72)
INR, mean (SD) 1.04 (0.10) 1.05 (0.12) 1.06 (0.11)
*Indicates statistically significant difference between items within the row at 
p<0.05 by z- test for proportions and t- test for means.
GCS, Glasgow Coma Scale; INR, international normalized ratio.
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Main results
Overall, 133 patients (40.7%) had an acute ICH and three 
patients (0.9%) had a delayed ICH (table 2). Of the patients 
with delayed ICH, one was on clopidogrel alone and the other 
two were on both clopidogrel and aspirin. When comparing by 
antiplatelet groups, patients on aspirin alone had a higher rate 
of acute ICH compared with the P2Y12 agents alone (48% vs 
30%; 18% difference, 95% CI 4% to 33%; p=0.016; OR 2.18, 
95% CI 1.15 to 4.13). There was no significant difference in rate 
of delayed ICH when comparing these groups (table 3).
When comparing patients on single antiplatelet therapy 
(aspirin or a P2Y12 inhibitor alone) with dual antiplatelet 
therapy (aspirin and a P2Y12 inhibitor), there were no signifi-
cant differences in the rates of acute or delayed ICH (table 3).
Of patients with acute ICH across all antiplatelet groups, most 
had either subdural or subarachnoid hemorrhages (table 4). Of 
the 191 patients with no initial ICH, 98 had a routine repeat 
head CT. No patients with an initial head CT negative for ICH 
had repeat imaging due to clinical change. All three patients with 
delayed ICH had subdural hemorrhages that were identified by 
routine repeat CT imaging (table 5). One patient with acute ICH 
did not have indication for repeat CT imaging documented. 
Neurosurgical intervention was required for nine patients with 
acute ICH. No patients with delayed ICH required intervention. 
No study patients died.
Patients with delayed ICH all sustained falls, had signs of head 
trauma and were older than 90 years. When compared with no 
ICH, patients with delayed ICH were older with mean age of 94 
vs 74 years (p=0.009), had a higher injury severity score (15.7 vs 
4.4, p<0.001) and trended towards a lower platelet count (141 
vs 216, p=0.053). No other variables predicted development of 
delayed ICH, including presenting symptoms, GCS, initial vital 
signs or INR.
DISCUSSION
In our study of 327 patients taking antiplatelet medications 
who sustained blunt head trauma, 40.7% were found to have 
an acute ICH. Nine required neurosurgical intervention and 
none died during the hospitalization. Only three patients 
(0.9%) with an initial negative head CT scan were found to 
have a delayed ICH on repeat head CT. These delayed ICH 
were all found on routine repeat head CT imaging, and not due 
to any clinical change. None of these patients required neuro-
surgical intervention and none died during the hospitalization.
As mounting evidence from the 1960s to the 1980s show low- 
dose aspirin to be an effective means of reducing cardiovascular 
risk, its use in adults has become widespread. An epidemiological 
analysis showed that nearly 30% of all adults aged 40 years or 
older in the USA self- report taking low- dose aspirin for primary 
or secondary cardiovascular disease (CVD) prevention, and 
the prevalence of aspirin use only increases with age.21 The US 
Preventive Services Task Force currently recommends low- dose 
aspirin use for primary CVD prevention and colorectal cancer.22 
Despite the known association between antiplatelet agents and 
increased bleeding risk in general, few studies have looked 
directly at the odds of acute or delayed traumatic ICH in patients 
taking these medications. Among these studies, rates of ICH in 
patients on antiplatelet medications presenting with blunt head 
trauma ranged from 3.6% to 67.3%.5
Although our study included all adult patients, our patient 
population had an average age of 76 years. Our high rate of 
ICH may be related to this factor. Prior research has shown that 
the geriatric population suffers from a higher rate of acute ICH. 
As the brain ages, there is volume loss, making bridging vein 
more vulnerable to bleeding along with decreased elasticity.23 
The aging US population has led to increased utilization of anti-
platelet medications, likely contributing to the increased inci-
dence of bleeds.24
The reported incidence of delayed ICH in the antiplatelet 
patient population is 0%–4%.10–16 These studies differed in their 
methodology and quality, several were retrospective, others were 
from trauma registries and some included patients on vitamin K 
antagonists. Our study found that the rate of delayed ICH is 
0.9%, on the lower end of the previously reported range. This 
suggests that admitting all patients taking antiplatelet medica-
tions with blunt head trauma and a negative initial head CT may 
Table 2 Antiplatelet category by head CT result for intracranial hemorrhage (ICH), no. (%; 95% CI)
No ICH Acute ICH Delayed ICH Total
Aspirin 66 (52%; 95% CI 43 to 60) 62 (48%; 95% CI 40 to 57) 0 (0%; 95% CI 0.0 to 2.8) 128
P2Y12 43 (68%; 95% CI 55 to 79) 19 (30%; 95% CI 19 to 43) 1 (1.6%; 95% CI 0.0 to 8.5) 63
Aspirin+P2Y12 82 (60%; 95% CI 52 to 69) 52 (38%; 95% CI 30 to 47) 2 (1.5%; 95% CI 0.2 to 5.2) 136
Total 191 (58%; 95% CI 53 to 64) 133 (41%; 95% CI 35 to 46) 3 (0.9%; 95% CI 0.2 to 2.7) 327
Table 3 Comparison of antiplatelet categories by head CT result for intracranial hemorrhage (ICH)
No ICH Acute ICH Delayed ICH
Aspirin vs P2Y12 52% vs 68%
−17%* (95% CI −31 to −2)
P=0.028
OR 0.50 (95% CI 0.26 to 0.93)
48% vs 30%
18% (95% CI 4 to 33)
P=0.016
OR 2.18 (95% CI 1.15 to 4.13)
0% vs 1.6%
−1.6% (95% CI −4.7 to 1.5)
P=0.153
Aspirin vs aspirin+P2Y12 52% vs 60%
−9%* (95% CI −21 to 3)
P=0.153
OR 0.70 (95% CI 0.43 to 1.14)
48% vs 38%
10% (95% CI −2 to 22)
P=0.094
OR 1.52 (95% CI 0.93 to 2.48)
0% vs 1.5%
−1.5% (95% CI −3.5 to 0.6)
P=0.168
P2Y12 vs aspirin+P2Y12 68% vs 60%
8% (95% CI −6 to 22)
P=0.280
OR 1.42 (95% CI 0.75 to 2.66)
30% vs 38%
−8% (95% CI −22 to 6)
P=0.269
OR 0.70 (95% CI 0.37 to 1.32)
1.6% vs 1.5%
0.1% (95% CI −3.5 to 3.8)
P=0.950
OR 1.08 (95% CI 0.10 to 12.14)
*Correct due to rounding.
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not be warranted. However, it may be prudent to admit nona-
genarians, with higher injury severity scores, and lower platelet 
counts.
While the association between anticoagulation and increased 
risk of traumatic ICH is well established in the literature, there 
are fewer studies quantifying the incidence of traumatic ICH 
in patients taking antiplatelet medications. Several studies have 
reported no increased risk for bleeding, mortality or neurosur-
gical interventions with antiplatelet medications.25–28 However, 
a meta- analysis with over 20 000 patients showed a pooled OR 
of 1.87 (95% CI 1.27 to 2.74) with increased odds of ICH for 
patients on all antiplatelet therapy, although not for patients on 
aspirin alone.5 This conflicting evidence highlights the need for 
more prospective trials on the effects of antiplatelet medica-
tions on ICH and the risk to patients. This information would 
be valuable as clinicians weigh the risks and benefits of anti-
platelet medications, especially in patients who are older with 
risk factors for falls.
Our results should be interpreted in the context of several 
limitations. First, as patients were enrolled retrospectively into 
this study from trauma registries, there likely were patients with 
head injuries who presented to the ED and were not seen by 
the trauma services. Second, antiplatelet use by patients was 
based on documentation in the medical records. Analysis with 
platelet function testing was not routinely performed, so it is 
unclear if patients were compliant with their antiplatelet medi-
cations. Third, the protocol for repeat head CT imaging was not 
universally applied. Many patients did not receive a repeat head 
CT, limiting the ability to quantify the rate of minor subclin-
ical delayed ICH. Fourth, no follow- up was performed after 
the hospitalization. Some patients may have had an acute ICH 
and were discharged to hospice, and others may have had a 
delayed ICH that occurred after hospital discharge. Although 
most delayed cases of ICH occur within the first 24 hours, 
some do occur up to 10 days after the initial head injury which 
would lead to under reporting of these cases. Finally, this study 
was not designed to have a control group with patients not on 
antiplatelets. Therefore, we could only perform comparisons 
between antiplatelet groups, rather than examine the effects 
of the individual agents on rates of ICH. Additionally, patients 
on antiplatelet agents may be more likely to receive a head CT 
compared with those who are not, which may lead to an increase 
in the ICH rate of limited clinical significance.
The findings of our study suggest that antiplatelet use increases 
the odds for the development of acute ICH after head trauma, 
with low risk for delayed ICH. Therefore, we recommend that 
all patients on antiplatelets with head injury have immediate 
head CT imaging. These results are generalizable to patients on 
the trauma service with head injury, who are potentially sicker 
than the overall emergency department population. However, 
even in these patients, we do not recommend routine admission 
for observation or repeat head CT imaging on asymptomatic 
patients with negative initial head CT imaging. These patients 
can safely be discharged home with outpatient follow- up and 
strict return precautions.
Our research adds to the previously conflicting evidence, 
demonstrating the need for additional investigation in this area. 
If future prospective studies confirm the increased rate of ICH 
in patients on antiplatelet medications with head injury, trauma 
activation guidelines may need to be amended to include these 
patients. In addition, identifying risk factors for ICH in patients 
taking antiplatelet agents may better inform physicians regarding 
the risk- benefit analysis in deciding on antiplatelet therapy.
Contributors Study conception and design: SMA, JJS, RDS, MJH, LMC, PGH. Data 
acquisition: BAM, NQT. Data analysis and interpretation: SMA, MJH, SWG. Initial 
draft: SMA, BAM, RDS, LMC, NQT. Critical revisions: SMA, BAM, JJS, RDS, LMC, SWG, 
PGH.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not- for- profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval This research study was approved by the MetroWest Institutional 
Review Board, MWMC IRB #00002845, and the Michigan State University human 
subjects research committee, study #1296, in addition to Sparrow Health System via 
collaborative agreement with Michigan State University.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement No data are available.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iDs
Scott M Alter http:// orcid. org/ 0000- 0003- 3824- 6308
Benjamin A Mazer http:// orcid. org/ 0000- 0002- 7500- 5725
Joshua J Solano http:// orcid. org/ 0000- 0001- 8408- 3189
Richard D Shih http:// orcid. org/ 0000- 0003- 4777- 6343
Mary J Hughes http:// orcid. org/ 0000- 0003- 1712- 1549
Lisa M Clayton http:// orcid. org/ 0000- 0001- 9729- 2676
Spencer W Greaves http:// orcid. org/ 0000- 0003- 0443- 7659
Nhat Q Trinh http:// orcid. org/ 0000- 0001- 9403- 4567
Patrick G Hughes http:// orcid. org/ 0000- 0002- 0073- 6961
REFERENCES
1. Ostini R, Hegney D, Mackson JM, Williamson M, Tett SE. Why is the use of clopidogrel 
increasing rapidly in Australia? an exploration of geographical location, age, sex and 
cardiac stenting rates as possible influences on clopidogrel use. Pharmacoepidemiol 
Drug Saf 2008;17:1077–90.
2. Postuła M, Akram S, Akram F. Current problems, new opportunities and future 
directions of anti- platelet therapy - increasing role of novel antiplatelet agents in 
cardiovascular diseases. Recent Pat Cardiovasc Drug Discov 2009;4:55–60.








EDH 0 (0%) 1 (5%) 0 (0%)
SDH 19 (31%) 8 (42%) 31 (60%)
SAH 19 (31%) 4 (21%) 14 (27%)
IPH 6 (10%) 2 (11%) 3 (6%)
SDH+SAH 12 (19%) 3 (16%) 2 (4%)
SDH+IPH 1 (2%) 0 (0%) 0 (0%)
SAH+IPH 3 (5%) 1 (5%) 1 (2%)
SDH+SAH+IPH 2 (3%) 0 (0%) 1 (2%)
EDH, epidural hemorrhage; IPH, intraparenchymal hemorrhage; SAH, subarachnoid 
hemorrhage; SDH, subdural hemorrhage.
Table 5 Head CT result for intracranial hemorrhage (ICH) by reason 
for repeat head CT, no. (%)
Routine Clinical change Not repeated Total
No ICH 98 (51%) 0 (0%) 93 (49%) 191
Acute ICH 122 (92%) 5 (4%) 5 (4%) 132*
Delayed ICH 3 (100%) 0 (0%) 3
Total 223 (68%) 5 (2%) 98 (30%) 326
*Missing indication for repeat head CT on one patient with acute ICH.
5Alter SM, et al. Trauma Surg Acute Care Open 2020;5:e000520. doi:10.1136/tsaco-2020-000520
Open access
3. Ohm C, Mina A, Howells G, Bair H, Bendick P. Effects of antiplatelet agents on 
outcomes for elderly patients with traumatic intracranial hemorrhage. J Trauma
2005;58:518–22.
4. Jones K, Sharp C, Mangram AJ, Dunn EL. The effects of preinjury clopidogrel use on 
older trauma patients with head injuries. Am J Surg 2006;192:743–5.
5. van den Brand CL, Tolido T, Rambach AH, Hunink MGM, Patka P, Jellema K. Systematic 
review and meta- analysis: is Pre- Injury antiplatelet therapy associated with traumatic 
intracranial hemorrhage? J Neurotrauma 2017;34:1–7.
6. Ivascu FA, Howells GA, Junn FS, Bair HA, Bendick PJ, Janczyk RJ. Predictors of 
mortality in trauma patients with intracranial hemorrhage on preinjury aspirin or 
clopidogrel. J Trauma 2008;65:785–8.
7. Melville LD, Shah K. Is antiplatelet therapy an independent risk factor for traumatic 
intracranial hemorrhage in patients with mild traumatic brain injury? Ann Emerg Med
2017;70:910–1.
8. Riccardi A, Frumento F, Guiddo G, Spinola MB, Corti L, Minuto P, Lerza R. Minor head 
injury in the elderly at very low risk: a retrospective study of 6 years in an emergency 
department (ED). Am J Emerg Med 2013;31:37–41.
9. Cea Soriano L, Gaist D, Soriano- Gabarró M, García Rodríguez LA. Incidence of 
intracranial bleeds in new users of low- dose aspirin: a cohort study using the health 
improvement network. J Thromb Haemost 2017;15:1055–64.
 10. Nishijima DK, Offerman SR, Ballard DW, Vinson DR, Chettipally UK, Rauchwerger AS, Reed
ME, Holmes JF, . Clinical Research in Emergency Services and Treatment (CREST) Network. 
Immediate and delayed traumatic intracranial hemorrhage in patients with head trauma 
and preinjury warfarin or clopidogrel use. Ann Emerg Med 2012;59:460–8.
 11. Tauber M, Koller H, Moroder P, Hitzl W, Resch H. Secondary intracranial hemorrhage 
after mild head injury in patients with low- dose acetylsalicylate acid prophylaxis. J 
Trauma 2009;67:521–5.
 12. Swap C, Sidell M, Ogaz R, Sharp A. Risk of delayed intracerebral hemorrhage in 
anticoagulated patients after minor head trauma: the role of repeat cranial computed 
tomography. Perm J 2016;20:14-6.
 13. Peck KA, Sise CB, Shackford SR, Sise MJ, Calvo RY, Sack DI, Walker SB, Schechter 
MS. Delayed intracranial hemorrhage after blunt trauma: are patients on 
preinjury anticoagulants and prescription antiplatelet agents at risk? J Trauma 
2011;71:1600–4.
 14. Chenoweth JA, Gaona SD, Faul M, Holmes JF, Nishijima DK, . Sacramento County 
Prehospital Research Consortium. Incidence of delayed intracranial hemorrhage in 
older patients after blunt head trauma. JAMA Surg 2018;153:570.
 15. Mann N, Welch K, Martin A, Subichin M, Wietecha K, Birmingham LE, Marchand 
TD, George RL. Delayed intracranial hemorrhage in elderly anticoagulated patients 
sustaining a minor fall. BMC Emerg Med 2018;18:27.
 16. Van Ornam J, Pruitt P, Borczuk P. Is repeat head CT necessary in patients with mild 
traumatic intracranial hemorrhage. Am J Emerg Med 2019;37:1694–8.
 17. National Institute for Health and Care Excellence. Head Injury: Assessment and early 
management. 2014. https://www. nice. org. uk/ guidance/ cg176 (25 Nov 2019).
 18. American College of Surgeons, Committee on Trauma. Resources for optimal care of 
the injured patient. Chicago: Ill American College of Surgeons, Committee on Trauma, 
2014.
 19. Sasser SM, Hunt RC, Sullivent EE, Wald MM, Mitchko J, Jurkovich GJ, Henry MC, 
Salomone JP, Wang SC, Galli RL, et al. Guidelines for field triage of injured patients. 
recommendations of the National expert panel on field triage. MMWR Recomm Rep 
2009;58:1–35.
 20. Jagoda AS, Bazarian JJ, Bruns JJ, Cantrill SV, Gean AD, Howard PK, Ghajar J, Riggio S, 
Wright DW, Wears RL, et al. Clinical policy: neuroimaging and decisionmaking in adult 
mild traumatic brain injury in the acute setting. Ann Emerg Med 2008;52:714–48.
 21. Stuntz M, Bernstein B. Recent trends in the prevalence of low- dose aspirin use for 
primary and secondary prevention of cardiovascular disease in the United States, 
2012-2015. Prev Med Rep 2017;5:183–6.
 22. Ebell MH. Uspstf recommendations: new and updated in 2016. Am Fam Physician 
2017;96:697–8.
 23. Adhiyaman V, Asghar M, Ganeshram KN, Bhowmick BK. Chronic subdural haematoma 
in the elderly. Postgrad Med J 2002;78:71–5.
 24. Hamidi M, Joseph B. Changing epidemiology of the American population. Clin Geriatr 
Med 2019;35:1–12.
 25. Galliazzo S, Bianchi MD, Virano A, Trucchi A, Donadini MP, Dentali F, Bertù L, Grandi 
AM, Ageno W. Intracranial bleeding risk after minor traumatic brain injury in patients 
on antithrombotic drugs. Thromb Res 2019;174:113–20.
 26. Grandhi R, Harrison G, Voronovich Z, Bauer J, Chen SH, Nicholas D, Alarcon LH, 
Okonkwo DO. Preinjury warfarin, but not antiplatelet medications, increases mortality 
in elderly traumatic brain injury patients. J Trauma Acute Care Surg 2015;78:614–21.
 27. Nishijima DK, Gaona SD, Waechter T, Maloney R, Blitz A, Elms AR, Farrales RD, 
Montoya J, Bair T, Howard C, et al. The incidence of traumatic intracranial hemorrhage 
in Head- Injured older adults transported by EMS with and without anticoagulant or 
antiplatelet use. J Neurotrauma 2018;35:750–9.
 28. Hamden K, Agresti D, Jeanmonod R, Woods D, Reiter M, Jeanmonod D. Characteristics 
of elderly fall patients with baseline mental status: high- risk features for intracranial 
injury. Am J Emerg Med 2014;32:890–4.
